Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the sale, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $71.15 on Wednesday. The stock has a market cap of $92,920.00, a P/E ratio of 7.60, a P/E/G ratio of -1.22 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same period last year, the company earned $2.75 EPS. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.92%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Insider Sells $5,509,508.29 in Stock” was reported by Week Herald and is owned by of Week Herald. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/11/15/insider-selling-gilead-sciences-inc-gild-insider-sells-5509508-29-in-stock.html.
A number of equities research analysts have issued reports on GILD shares. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Thursday, August 31st. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective for the company. in a research note on Monday, August 28th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday, September 6th. Finally, Oppenheimer Holdings, Inc. assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They set a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $84.87.
Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after acquiring an additional 310,607 shares during the period. FMR LLC lifted its position in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Finally, Parnassus Investments CA lifted its position in shares of Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after acquiring an additional 4,556,901 shares during the period. Hedge funds and other institutional investors own 74.62% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.